| AVBP | SC 13D/A | bearish | 5/10 | OrbiMed Advisors filed Amendment No. 2 to its Schedule 13D for ArriVent BioPharma (AVBP), reporting a reduction in benef | Oct 8, 2026 |
| PBYI | SC 13D/A | neutral | 3/10 | Alan H. Auerbach, CEO and President of Puma Biotechnology, filed an amended Schedule 13D reporting that his 2011 warrant | Oct 6, 2026 |
| ABUS | SC 13D/A | neutral | 4/10 | Roivant Sciences Ltd. filed Amendment No. 14 to its Schedule 13D on Arbutus Biopharma Corp, reporting beneficial ownersh | Oct 5, 2026 |
| ADRX | SC 13D | neutral | 5/10 | SR One Capital Management, led by Simeon George, filed a Schedule 13D disclosing beneficial ownership of 9,936,661 share | Oct 5, 2026 |
| ADRX | SC 13D | neutral | 5/10 | OrbiMed Advisors LLC and affiliated entities filed a Schedule 13D disclosing beneficial ownership of 14,913,764 shares o | Oct 2, 2026 |
| GNTA | SC 13D/A | neutral | 4/10 | This Amendment No. 1 to Schedule 13D reports a decrease in the group's beneficial ownership percentage from 11.50% to 11 | Oct 2, 2026 |
| CELZ | SC 13D | neutral | 4/10 | CEO Timothy Warbington and his entity Creative Acquisition Corp. filed a Schedule 13D disclosing beneficial ownership of | Oct 1, 2026 |
| SLBT | SC 13D/A | neutral | 3/10 | Ching-Dong Wang and SL Link Holding Ltd. filed an amendment to Schedule 13D, reporting beneficial ownership of 333,832,1 | Oct 1, 2026 |
| KOD | SC 13D/A | bullish | 7/10 | Baker Bros. Advisors LP filed Amendment No. 12 to its Schedule 13D for Kodiak Sciences Inc., reporting a massive open-ma | Sep 30, 2026 |
| GOSS | SC 13D/A | bearish | 6/10 | D. E. Shaw's Amendment No. 4 to its Schedule 13D on Gossamer Bio reports that its Valence portfolio crossed below the 5% | Sep 28, 2026 |
| MEDP | SC 13D/A | neutral | 4/10 | August J. Troendle, CEO and founder of Medpace, filed Amendment No. 24 to his Schedule 13D, reporting a reduction in his | Sep 28, 2026 |
| LFCR | SC 13D/A | bullish | 7/10 | Legion Partners Asset Management filed an amended Schedule 13D disclosing that Lifecore Biomedical entered into a defini | Sep 28, 2026 |
| CELU | SC 13D/A | bearish | 7/10 | The Philip & Daniele Barach Family Trust filed Amendment No. 3 to its Schedule 13D, reporting a significant escalation i | Sep 28, 2026 |
| ETRA | SC 13D | neutral | 5/10 | OrbiMed Advisors, a healthcare-focused investment firm, filed a Schedule 13D disclosing beneficial ownership of 6,885,17 | Sep 25, 2026 |
| TBPH | SC 13D/A | neutral | 4/10 | Weiss Asset Management LP filed a Schedule 13D/A reporting that its stake in Theravance Biopharma was reduced to 0% as o | Sep 25, 2026 |
| SKYE | SC 13D/A | bearish | 6/10 | 5AM Partners VII, LLC and affiliated entities filed Amendment No. 6 to their Schedule 13D on Skye Bioscience, reporting | Sep 24, 2026 |
| PRFX | SC 13D | bullish | 7/10 | S.H.N. Financial Investments Ltd., an Israeli investment firm controlled by Hadar Shamir and Nir Shamir, filed a Schedul | Sep 24, 2026 |
| NAMS | SC 13D/A | bullish | 5/10 | Frazier Life Sciences funds filed Amendment No. 7 to their Schedule 13D on NewAmsterdam Pharma, reporting open-market pu | Sep 22, 2026 |
| PDSB | SC 13D | bullish | 7/10 | Nant Capital LLC, controlled by Dr. Patrick Soon-Shiong, filed a Schedule 13D disclosing a 19.9% beneficial stake in PDS | Sep 21, 2026 |
| SION | SC 13D/A | bearish | 7/10 | RA Capital Management has filed Amendment No. 2 to its Schedule 13D, reporting a massive reduction in its stake in Sionn | Sep 21, 2026 |
| TVGN | SC 13D/A | neutral | 4/10 | Ryan H. Saadi filed Amendment No. 4 to his Schedule 13D, disclosing receipt of 8,000,000 restricted shares of Tevogen co | Sep 16, 2026 |
| TVGN | SC 13D/A | neutral | 3/10 | Kirti Desai filed an amended Schedule 13D disclosing a grant of 750,000 restricted shares on September 14, 2026, increas | Sep 16, 2026 |
| LODE | SC 13D/A | bearish | 5/10 | MAK Capital Fund LP filed Amendment No. 1 to its Schedule 13D on Comstock Inc. (LODE), reporting a reduction in its bene | Sep 16, 2026 |
| VNRX | SC 13D/A | neutral | 3/10 | Lagoda Investment Management filed an amended Schedule 13D for VolitionRx, reporting a 5.9% stake (1,650,505 shares) as | Sep 16, 2026 |
